Mankind Pharma Limited (BOM:543904)
2,352.90
-8.35 (-0.35%)
At close: Jun 6, 2025
Mankind Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2019 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2019 - 2020 |
Revenue | 122,074 | 103,348 | 87,494 | 77,816 | 62,144 | Upgrade
|
Revenue Growth (YoY) | 18.12% | 18.12% | 12.44% | 25.22% | 5.83% | Upgrade
|
Cost of Revenue | 34,890 | 33,207 | 30,031 | 24,879 | 18,471 | Upgrade
|
Gross Profit | 87,184 | 70,141 | 57,463 | 52,937 | 43,673 | Upgrade
|
Selling, General & Admin | 26,924 | 29,018 | 23,126 | 20,934 | 18,195 | Upgrade
|
Other Operating Expenses | 30,081 | 15,622 | 15,195 | 12,014 | 8,386 | Upgrade
|
Operating Expenses | 63,217 | 48,622 | 41,580 | 34,614 | 27,770 | Upgrade
|
Operating Income | 23,967 | 21,518 | 15,883 | 18,322 | 15,903 | Upgrade
|
Interest Expense | -4,294 | -286 | -402.74 | -557.8 | -193.03 | Upgrade
|
Interest & Investment Income | - | 400.53 | 127.67 | 129.25 | 387.27 | Upgrade
|
Earnings From Equity Investments | 122.4 | 152.14 | 124.24 | 144.48 | 116.77 | Upgrade
|
Currency Exchange Gain (Loss) | - | 86.36 | 104.06 | 88.45 | 5.02 | Upgrade
|
Other Non Operating Income (Expenses) | 5,368 | 878.52 | 536.42 | 486 | 51.17 | Upgrade
|
EBT Excluding Unusual Items | 25,163 | 22,750 | 16,372 | 18,613 | 16,270 | Upgrade
|
Impairment of Goodwill | - | - | -38.52 | - | - | Upgrade
|
Gain (Loss) on Sale of Investments | - | 1,295 | 374.31 | 1,129 | 628.65 | Upgrade
|
Gain (Loss) on Sale of Assets | - | 4.8 | 16.65 | -37.41 | -30.45 | Upgrade
|
Asset Writedown | - | -91.63 | -97.08 | -57.63 | -38.88 | Upgrade
|
Other Unusual Items | - | 24.79 | 41.53 | 85.27 | 77.21 | Upgrade
|
Pretax Income | 25,163 | 23,994 | 16,712 | 19,746 | 16,916 | Upgrade
|
Income Tax Expense | 5,097 | 4,576 | 3,616 | 5,216 | 3,986 | Upgrade
|
Earnings From Continuing Operations | 20,066 | 19,418 | 13,097 | 14,530 | 12,930 | Upgrade
|
Earnings From Discontinued Operations | 45.3 | - | - | - | - | Upgrade
|
Net Income to Company | 20,111 | 19,418 | 13,097 | 14,530 | 12,930 | Upgrade
|
Minority Interest in Earnings | -201.6 | -288.75 | -278.17 | -194.81 | -276.07 | Upgrade
|
Net Income | 19,910 | 19,129 | 12,819 | 14,335 | 12,654 | Upgrade
|
Net Income to Common | 19,910 | 19,129 | 12,819 | 14,335 | 12,654 | Upgrade
|
Net Income Growth | 4.08% | 49.23% | -10.58% | 13.28% | 22.81% | Upgrade
|
Shares Outstanding (Basic) | 404 | 401 | 401 | 401 | 401 | Upgrade
|
Shares Outstanding (Diluted) | 405 | 401 | 401 | 401 | 401 | Upgrade
|
Shares Change (YoY) | 0.87% | 0.14% | 0.00% | - | - | Upgrade
|
EPS (Basic) | 49.28 | 47.75 | 32.00 | 35.78 | 31.59 | Upgrade
|
EPS (Diluted) | 49.20 | 47.68 | 32.00 | 35.78 | 31.59 | Upgrade
|
EPS Growth | 3.19% | 49.00% | -10.57% | 13.27% | 22.82% | Upgrade
|
Free Cash Flow | 19,526 | 18,371 | 10,243 | 4,549 | 8,318 | Upgrade
|
Free Cash Flow Per Share | 48.25 | 45.79 | 25.57 | 11.36 | 20.77 | Upgrade
|
Gross Margin | 71.42% | 67.87% | 65.68% | 68.03% | 70.28% | Upgrade
|
Operating Margin | 19.63% | 20.82% | 18.15% | 23.55% | 25.59% | Upgrade
|
Profit Margin | 16.31% | 18.51% | 14.65% | 18.42% | 20.36% | Upgrade
|
Free Cash Flow Margin | 16.00% | 17.78% | 11.71% | 5.85% | 13.38% | Upgrade
|
EBITDA | 30,179 | 25,366 | 19,051 | 19,910 | 17,038 | Upgrade
|
EBITDA Margin | 24.72% | 24.54% | 21.77% | 25.59% | 27.42% | Upgrade
|
D&A For EBITDA | 6,212 | 3,848 | 3,168 | 1,588 | 1,135 | Upgrade
|
EBIT | 23,967 | 21,518 | 15,883 | 18,322 | 15,903 | Upgrade
|
EBIT Margin | 19.63% | 20.82% | 18.15% | 23.55% | 25.59% | Upgrade
|
Effective Tax Rate | 20.26% | 19.07% | 21.63% | 26.42% | 23.56% | Upgrade
|
Revenue as Reported | 127,442 | 106,156 | 88,780 | 79,776 | 63,854 | Upgrade
|
Advertising Expenses | - | 6,039 | 3,737 | 4,516 | 3,857 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.